Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | CCR1 | P32246 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3448493 | 0.89 | CCR1 (0.41) | TP53MAPTSMN1; SMN2CCR1EPHX2 | |
| SCHEMBL3448425 | 0.87 | CCR1 (0.41) | TP53MAPTCCR1EPHX2LMNA | |
| SCHEMBL3449911 | 0.85 | CCR1 (0.38) | CNR1TP53MAPTSMN1; SMN2CCR1 | |
| SCHEMBL3450307 | 0.85 | CCR1 (0.38) | CNR1TP53MAPTSMN1; SMN2CCR1 | |
| SCHEMBL3450194 | 0.84 | CCR1 (0.44) | CCR1EPHX2 | |
| SCHEMBL3450336 | 0.81 | CCR1 (0.41) | CNR1TP53MAPTSMN1; SMN2CCR1 | |
| SCHEMBL3450650 | 0.80 | CCR1 (0.40) | CCR1EPHX2DRD2HTR2ADRD3 | |
| SCHEMBL3452171 | 0.80 | CCR1 (0.35) | CNR1TP53MAPTSMN1; SMN2CCR1 | |
| SCHEMBL3450732 | 0.78 | CCR1 (0.39) | CCR1EPHX2 | |
| SCHEMBL3448290 | 0.78 | CCR1 (0.39) | CCR1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820673-B2 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-26 | — | — | US | disclosed |
| EP-1695961-A1 | UREA DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | F2, URB2, F12 | CNR1 264/4885TP53 2996/4885MAPT 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.